Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 16/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16712648 | 0.87 | HRH3 (0.43) | HRH3KCNH2HTR1ADRD2 | |
| SCHEMBL16702159 | 0.87 | MAOA (0.41) | HRH3MAOAMAOBHTR1ADRD2 | |
| SCHEMBL16703990 | 0.86 | MAOA (0.39) | HRH3MAOAMAOBHTR1ADRD2 | |
| SCHEMBL16702411 | 0.86 | KCNH2 (0.45) | HRH3KCNH2MAOAMAOBADRB2 | |
| SCHEMBL16701857 | 0.86 | DRD2 (0.55) | HTR1ADRD2 | |
| SCHEMBL16702060 | 0.82 | HRH3 (0.58) | HRH3KMT2A | |
| SCHEMBL16701815 | 0.81 | GPR119 (0.43) | KCNH2HTR1ADRD2ADRB2MEN1 | |
| SCHEMBL16712642 | 0.79 | HRH3 (0.55) | HRH3 | |
| SCHEMBL16701992 | 0.76 | HRH3 (0.53) | HRH3HTR1ADRD2 | |
| SCHEMBL16712645 | 0.75 | DRD2 (0.63) | HTR1ADRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2015069110-A1 | MULTIPLE D2 A(NTA)GONISTS/H3 ANTAGONISTS FOR TREATMENT OF CNS-RELATED DISORDERS | AAPA B.V. (NL) | 2015-05-14 | — | — | WO | disclosed |